Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition.

@article{Chen2017AnthelminthicDN,
  title={Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition.},
  author={Liping Chen and Li Wang and Haibin Shen and Hui Lin and Dan Li},
  journal={Biochemical and biophysical research communications},
  year={2017},
  volume={484 2},
  pages={
          416-421
        }
}
  • Liping Chen, L. Wang, +2 authors D. Li
  • Published 2017
  • Biology, Medicine
  • Biochemical and biophysical research communications
Drug repurposing represents an alternative therapeutic strategy to cancer treatment. The potent anti-cancer activities of a FDA-approved anthelminthic drug niclosamide have been demonstrated in various cancers. However, whether niclosamide is active against cervical cancer is unknown. In this study, we investigated the effects of niclosamide alone and its combination with paclitaxel in cervical cancer in vitro and in vivo. We found that niclosamide significantly inhibited proliferation and… Expand
Targeting Wnt/β‐catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer
TLDR
It is demonstrated that niclosamide, an anthelmintic drug, is a potential sensitizing candidate for overcoming chemoresistance in esophageal cancer and its underlying mechanism is Wnt/β‐catenin inhibition is a sensitizing strategy in esophileal cancer. Expand
Antihelminthic Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells In Vitro and In Vivo
TLDR
Niclosamide induced apoptosis by activating the intrinsic and caspase-independent pathway in human A549 and CL1-5 non-small cell lung cancer cells, and is a potential candidate for anti-NSCLC therapy. Expand
Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents
TLDR
It was demonstrated that niclosamide suppressed the STAT3 signaling pathway in esophageal adenocarcinoma cells (BE3) and esophAGEal squamous cell carcinoma Cells (CE48T and CE81T) and induced cell apoptosis as determined by Annexin V and PI staining. Expand
Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β
TLDR
A novel mechanistic insight is provided for anti-cancer efficacy of Nic by increasing p-Gsk3β that modulates molecular signaling(s), including inhibition of hedgehog (Hh) signaling-mediated cellular proliferation and increased apoptosis through mTORC1-dependent autophagy may prove helpful for the development of novel PC therapies. Expand
Dihydroartemisinin as a Sensitizing Agent in Cancer Therapies
TLDR
How DHA sensitizes cancer cells to anti-cancer therapies is summarized, its molecular mechanisms and pharmacological effects in vitro and in vivo as well as in current clinical trials are highlighted, and potential issues concerning DHA are discussed. Expand
A new niclosamide derivatives‐B17 can inhibit urological cancers growth through apoptosis‐related pathway
TLDR
Niclosamide and B17 derivative had good ability in inhibition proliferation and migratory ability in T24, Caki‐1, and DU145 cells without prominent morphology and apoptotic body changes. Expand
Effective and new potent drug combination: Histone deacetylase and Wnt/β‐catenin pathway inhibitors in lung carcinoma cells
Lung cancer is the most commonly diagnosed cancer worldwide with a high mortality rate. In this study, the therapeutic effect of combination valproic acid and niclosamide was investigated on humanExpand
Repurposing of Anthelminthics as Anticancer Drugs
TLDR
Anthelminthics poorly fulfill the preconditions of a specific mode of anticancer action and availability of pharmacokinetic and pharmacodynamic data for a favorable repurposing as anticancer drugs. Expand
Inhibition of DNA Double-Strand Break Repair by Niclosamide in Human Colorectal Cancer Cells
TLDR
Niclosamide possesses a radiosensitizing effect on human colorectal cancer cells, which is based on inhibition of DNA DSB repair induced by γ-radiation. Expand
Targeting mitochondrial respiration as a therapeutic strategy for cervical cancer.
TLDR
Atovaquone inhibited proliferation and induced apoptosis with varying efficacy among cervical cancer cell lines regardless of HPV infection, cellular origin and their sensitivity to paclitaxel, suggesting that the mitochondrial biogenesis varies among patients with cervical cancer. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 31 REFERENCES
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
TLDR
The inhibitory effects of niclosamide on cancer stem cells provide further evidence for its consideration as a promising drug for cancer therapy. Expand
Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
TLDR
This work shows that all three agents significantly decreased the expression of proteins in the Wnt/β-catenin, mTOR and STAT3 pathways and preferentially targeted cells that expressed the ovarian CSC surface protein CD133, which illustrates the potential of drug repurposing for chemoresistant EOC. Expand
Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer.
Targeting mitochondrial biogenesis has become a potential therapeutic strategy in cancer due to their unique metabolic dependencies. In this study, we show that levofloxacin, a FDA-approvedExpand
Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
TLDR
These studies support niclosamide as a promising therapy for ovarian cancer and warrant further preclinical and clinical evaluation of this safe, clinically proven drug for the management of this devastating gynecologic malignancy. Expand
Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
TLDR
This work is the first to demonstrate that niclosamide is a potential drug to overcome resistance to BCR-ABL TKI treatment in BP-CML and suggest the therapeutic value of Erk/Mnk/eIF4E in CML treatment. Expand
Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer
TLDR
In vivo study showed that niclosamide or combination with cisplatin could repress the growth of xenografts originated from either 231-CS or 231-CR cells, with prominent suppression of Ki67 expression, which suggested that Niclosamide might serve as a novel therapeutic strategy for triple-negative breast cancer treatment, especially those resistant to cisPlatin. Expand
Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration
TLDR
PP is evaluated as a novel anti-cancer drug that targets mitochondrial respiration that inhibited the unfolded protein response induced by glucose starvation, thereby inhibiting the proliferation of pancreatic cancer cells. Expand
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.
TLDR
Niclosamide inhibited Wnt/β-Catenin pathway activation, downregulated Dvl2, decreased downstream β-catenin signaling, and exerted antiproliferative effects in human colon cancer cell lines and CRC cells isolated by surgical resection of metastatic disease, regardless of mutations in APC. Expand
Autophagy promotes paclitaxel resistance of cervical cancer cells: involvement of Warburg effect activated hypoxia-induced factor 1-α-mediated signaling
TLDR
A possible Warburg effect activated HIF1-α-mediated signaling-induced autophagic pathway is proposed, which may provide new insight into paclitaxel chemoresistance. Expand
Drug Screening Identifies Niclosamide as an Inhibitor of Breast Cancer Stem-Like Cells
TLDR
The results of this proof-of-principle study may facilitate the development of new breast cancer therapies in the near future and the extension of niclosamide clinical trials is warranted. Expand
...
1
2
3
4
...